Home > Boards > US Listed > Biotechs > Actinium Pharmaceuticals, Inc. (ATNM)

From December 8th at Benzinga Global Small Cap

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 21
Posts 1,598
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2021 5:01:48 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/31/2021 5:01:49 PM
Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy Seeking Alpha - 3/24/2021 8:10:31 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 4:45:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2020 5:01:19 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2020 4:18:50 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2020 4:16:20 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/23/2020 5:02:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/7/2020 5:02:07 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/7/2020 5:01:10 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/17/2020 6:21:29 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:23:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:22:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:19:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:18:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/14/2020 5:07:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:05:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:05:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:04:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:03:59 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/12/2020 6:01:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2020 4:32:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 5:11:05 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 7/13/2020 5:10:51 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/30/2020 6:32:21 AM
stockguard   Tuesday, 12/29/20 03:34:15 PM
Re: None
Post # of 2569 
From December 8th at Benzinga Global Small Cap Conference Day 1 Recap:
Actinium Pharmaceuticals Says SIERRA Trial Has Demonstrated All Patients Receiving Therapeutic Dose Of Iomab-B Have Been Able To Go On to Bone Marrow Transplant
Actinium Pharmaceuticals Says Estimates ~176K Patients/Year Diagnosed With Blood Cancers Treatable With Bone Marrow Transplant But Only 23K Transplants Performed In 2018, Says Looking To Address Access Gap With Iomab-B
Actinium Pharmaceuticals CFO Steve O'Loughlin Notes Co.'s ARCs Enable Targeted Radiotherapy Directly To Cancer Cells; Says Has Over 130 Patents That Protect Candidates Through 2037 And Beyond
Actinium Pharmaceuticals CFO Steve O'Loughlin Highlights Co. Balance Sheet; ~$48M In Cash, Which Can Fund Operations Through 2021
Actinium Pharmaceuticals CFO Steve O'Loughlin Says Co. Led By Iomab-B, Which Is In Phase 3 SIERRA Trial; Has Also Expanded Into Bone Marrow, Transplant CAR-T And Gene Therapy
Actinium Reports 67% Overall Response Rate In First Cohort In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML At ASH 2020


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences